Avara Pharmaceutical Services

avara.com

Home Avara Pharmaceutical Services is a state of the art Contract Manufacturing Organization. We focus our efforts on Quality, Compliance, Customer Service, and delivering on time and in-full. We have a senior leadership that have managed manufacturing infrastructures worldwide. Avara Pharmaceutical Services was founded by a team of industry veterans who, through personal experience, understand both sides of the contract manufacturing market. Our team is fully aware of customers’ expectations. Therefore, we built a CDMO that provides exceptional service and a world-class experience by delivering on our commitments. These commitments include delivering to scope, schedule, meeting regulatory requirements and quality standards, all at an agreed and fair price.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

news image

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More

Business Insights

TRIRX PARTNERSHIP WITH LIVERPOOL CITY REGION ADVANCES BIOTECH CAPABILITIES

PRnewswire | July 28, 2023

news image

TriRx Pharmaceutical Services, LLC, a Contract Development and Manufacturing Organization (CDMO), welcomed the UK Government's recent announcement on England's second Investment Zone, focused on Life Sciences in the Liverpool City Region. TriRx Speke Ltd. is the first investor and is well-positioned to further advance its capabilities by adding upstream technologies to manufacture monoclonal antibodies to an existing large-scale biotech purification facility. The current...

Read More

A FAST-MOVING VIRUS PITS TREATING PATIENTS AGAINST FINDING A CURE

Bloomberg | April 05, 2020

news image

The frenzied hunt for drugs to ease Covid-19 could make it more difficult for scientists to find lasting treatments. Pharmaceutical-research experts are raising concerns that attempts to offer desperate coronavirus patients some form of treatment may hobble crucial studies of which drugs actually work and which ones don't. More than 100 off-the-shelf and experimental therapies are being tested either formally or informally for the coronavirus disease, including hydroxychloroquine, the antima...

Read More

Pharmacy Market

ATHENEX, INC. REACHES AGREEMENT WITH LENDERS TO PURSUE EXPEDITED SALES PROCESS

Globenewswire | May 16, 2023

news image

Athenex, Inc. a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy. To be...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More
news image

Business Insights

TRIRX PARTNERSHIP WITH LIVERPOOL CITY REGION ADVANCES BIOTECH CAPABILITIES

PRnewswire | July 28, 2023

TriRx Pharmaceutical Services, LLC, a Contract Development and Manufacturing Organization (CDMO), welcomed the UK Government's recent announcement on England's second Investment Zone, focused on Life Sciences in the Liverpool City Region. TriRx Speke Ltd. is the first investor and is well-positioned to further advance its capabilities by adding upstream technologies to manufacture monoclonal antibodies to an existing large-scale biotech purification facility. The current...

Read More
news image

A FAST-MOVING VIRUS PITS TREATING PATIENTS AGAINST FINDING A CURE

Bloomberg | April 05, 2020

The frenzied hunt for drugs to ease Covid-19 could make it more difficult for scientists to find lasting treatments. Pharmaceutical-research experts are raising concerns that attempts to offer desperate coronavirus patients some form of treatment may hobble crucial studies of which drugs actually work and which ones don't. More than 100 off-the-shelf and experimental therapies are being tested either formally or informally for the coronavirus disease, including hydroxychloroquine, the antima...

Read More
news image

Pharmacy Market

ATHENEX, INC. REACHES AGREEMENT WITH LENDERS TO PURSUE EXPEDITED SALES PROCESS

Globenewswire | May 16, 2023

Athenex, Inc. a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy. To be...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us